VCBeat Health Contact Us
Home AtaCor Medical Secures $75M Funding to Advance Pivotal Trial for AtaCor System, a Novel Extravascular ICD Challenging Medtronic's Dominance

AtaCor Medical Secures $75M Funding to Advance Pivotal Trial for AtaCor System, a Novel Extravascular ICD Challenging Medtronic's Dominance

Oct 07, 2025 10:02 CST Updated 10:02
AtaCor Medical

Cardiac Pacemaker Developer

AtaCor MedicalAnnounced that it has reached a financing agreement of up to 75 million US dollars. The funds raised will be used to support its pivotal study with the US FDA, which aims to evaluate itsNon-Vascular ICD---AtaCor SystemUseFor the treatment of life-threatening ventricular tachyarrhythmias.

图片

Executive Evaluation

"The market demand for extravascular ICDs is clear and growing. These systems offer both the simplicity of implantation procedures and the ability to provide comprehensive rapid arrhythmia treatment using a small pulse generator. AtaCor Medical is well-positioned to meet this demand. We are proud to have completed this round of financing and look forward to launching our pivotal trial next year."

---Rick Sanghera  CEO of AtaCor Medical

"AtaCor team is developing a meaningful solution for patients while preserving the integrity of the heart and leaving room for future interventions. The board is pleased to see this injection of funding to support AtaCor's pivotal trial, bringing this important technology one step closer to clinical application."

---Maria Berkman  Chairman of the Board of AtaCor Medical

If cardiac arrest occurs, the heart will lose its pumping ability.Force, leading to largeIschemia and hypoxia of the brain and vital organs throughout the body, posing a critical threatLife.At this point, timely defibrillation treatment is needed to help the patient restore their normal heart rhythm.However, due to the sudden onset, it is difficult to find an automated external defibrillator (AED) for timely treatment in a short period. Once the optimal treatment window is missed, patients often die within one to several hours.According to statistics, every year in ChinaOccurrenceSudden Cardiac DeathThe number of deaths exceeds 540,000, while the success rate of out-of-hospital rescue is less than 1%.

The Implantable Cardioverter Defibrillator (ICD) can solve this thorny issue. By implanting a miniaturized defibrillator into the patient’s body, it provides 24-hour continuous monitoring of the heart condition and delivers rapid defibrillation in the event of sudden cardiac arrest, akin to providing the patient with a "cardiac bulletproof vest." Despite the conventionalImplantable CardiacImplantable Cardioverter Defibrillator (ICD) can help patients in a timely mannerDefibrillation saves patients' lives, but traditional ICDs have two major drawbacks:Damage and infection of the lead.Since the leads are adhered to the heart and veins, lead extraction is not an easy task (many centers do not perform it). The incidence of severe complications from percutaneous lead extraction is 1-2%, with a mortality rate of 0.1%. Additionally, for pediatric and adolescent patients, growth and development are unavoidable issues, and multiple surgeries significantly increase the risk of infection.Probability。
To solve through blood vesselsLead issues, mainstream companies are actively addressingExtravascular Defibrillator. Currently, only Medtronic's Aurora EV-ICD extravascular defibrillator has received FDA, NMPA, and CE approval for marketing, becoming a new option for patients. DespiteAurora EV-ICD is very good, but the market needs more options.AndAtaCor MedicaNon-Vascular ICD---AtaCor SystemBecoming the Market ApartAurora EV-ICDIn addition, another new choice.


AtaCor System
AtaCor SystemBy wireAtala andComposition of the implantable pulse generator.
  • Atala
AtalaIt is a revolutionary EV-ICD lead that is compatible with all marketed products.Transvenous ICD.AtalaCan be mentionedProviding reliable sensing, pacing, and shock therapy to treat life-threatening arrhythmias, while avoiding entry into the heart and vascular system to reduce unnecessary complications.
图片
Advantages of Atala over traditional leads
  • Unlike subcutaneous ICDs that cannot provide antitachycardia pacing (ATP) therapy, Atala achieves both ATP and shock therapy through a single lead and a single procedure.
  • AtalaSpecifically designed to enhance patient comfort, it is compatible with smaller and thinner commercially available transvenous ICDs (compared to subcutaneous ICDs). This feature not only improves the aesthetic appearance and comfort after device implantation but also significantly reduces pain perception during ATP therapy.
  • AtalaRaising the Standard for Cardiac Rhythm Management --- Its proprietary design features optimize the implantation process of extravascular ICD leads while enabling seamless integration of ATP and shock therapy through commercially available transvenous ICDs.
  • Implantable Pulse Generator
The pulse generator can be placed in a lateral or subcutaneous pocket in the chest, offering a new option for the EV-ICD system.
AtaCor System Advantages
  • Avoid corresponding vascular complications (e.g., arteriovenous fistula);
  • Retain the complete blood delivery system without affecting blood flow;
  • Provide solutions for those who cannot have pacemaker leads implanted intravenously or have poor treatment outcomes;
  • Shorter operation time, no X-ray required;
  • Reduce the cost and surgical risks for medical institutions.

AtaCor System Demonstration

AtaCor Medical
Atacor MedicalAtaCor Medical, Inc. is an innovative medical device company dedicated to transforming cardiac rhythms through novel extravascular catheters and deployment systems, aiming to eliminate the risks, costs, and drawbacks associated with traditional transvenous leads.
图片
图片